FDA Warns Eye Care Company Conducting Unapproved Clinical Trial Of Drug-Device Product
Executive Summary
The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.
You may also be interested in...
Ophthalmic Dispensers Recommended Class I Designation By FDA Panel
The FDA’s Ophthalmic Devices Panel approved a Class I designation for ophthalmic dispensers, which were reclassified from drugs to devices after the Genus v. FDA decision.
News We're Watching – 27 January
This feature compiles news briefs on a range of US regulatory and legal happenings. This week: Medtronic seeks HeartWare batteries; companies sign health equity pledge; insulin dosing app cleared; recall on field decontamination kits; and the renewal of an FDA panel.
Expert: FTC Clinical Data Requirements A Likely Challenge For Medtech Companies
Medtech Insight spoke to Sidley Austin LLP partner Jeff Senger about the challenges companies may face navigating the FTC’s updated health products guidance.